Reducing prophylactic antibiotic costs in cardiovascular surgery: the role of the clinical pharmacist.
A project was undertaken to demonstrate significant drug cost savings from clinical pharmacy services. The method of identifying and documenting the problem and the presentation and implementation of the project are discussed. The cost savings of the project are presented, including the economic impact on the patient and institution. The clinical pharmacist, the key figure in the success of the project, presented a complete pharmacological and financial analysis of the project to the medical staff. The project resulted in a financial savings of approximately $600 000/yr to patients in decreased drug charges, $200 000/yr in decreased drug purchases/inventory, and $105 000/yr to the hospital in an improved revenue/expense statement. This project represents an example of the important role of the clinical pharmacist in helping a hospital identify areas to reduce drug therapy costs. A future role for clinical pharmacists will be to work closely with the director of pharmacy, hospital administration, and medical staff in identifying and implementing cost-effective drug therapy.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D013504:Cardiovascular Surgical Procedures; D002511:Cephalosporins / Q000627:therapeutic use; D003363:Cost Control / Q000379:methods; D006746:Hospital Bed Capacity, 500 and over; D006801:Humans; D008910:Minnesota; D010607:Pharmacy Service, Hospital / Q000191:economics*; D011292:Premedication / Q000191:economics*; D013530:Surgical Wound Infection / Q000517:prevention & control*
D000900:Anti-Bacterial Agents; D002511:Cephalosporins